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1. Introduction
   Cancer is a non-communicable disease and continues to 
represent the second largest cause of mortality in the world. 
The prevention and control of cancer in developed and 
developing countries deserve urgent attention because it is 
expected to be double in the next 20 to 25 years[1]. Research in 
the field of cancer eradication is going on all over the world 
and a number of clinically used drugs/methods have already 
been developed but most of them were ineffective against 
devastating cancer due to divergences of cancer. During the 
past decade, cancer drugs discovery or development is based 
on the single-target, single-compound paradigm. These 
conventional treatments modalities are self limited due to 
their major side effects and it prompted to development of 
many new approaches for the treatment of cancer and this 
concept contrasts with a more recent drug design approach, 
where a single drug can target with high efficacy multiple 
steps in cancer progression. Such second-generation drugs 
are often much more efficacious with little side effects. One 
such example involves the use of live, attenuated bacteria or 
their purified products or secondary metabolites. The mode 
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Objective: To find out the effective anticancer drugs from bacterial products, petroleum ether 
extract of Corynebacterium xerosis. 
Methods: Antiproliferative activity of the metabolite has been measured by monitoring the 
parameters like tumor weight measurement, tumor cell growth inhibition in mice and survival 
time of tumor bearing mice, etc. Hepatoprotective effect of the metabolites was determined by 
observing biochemical, hematological parameters.
Results: It has been found that the petroleum ether extract bacterial metabolite significantly 
decrease cell growth (78.58%; P<0.01), tumor weight (36.04 %; P<0.01) and increase the life 
span of tumor bearing mice (69.23%; P<0.01) at dose 100 mg/kg (i.p.) in comparison to those of 
untreated Ehrlich ascites carcinoma (EAC) bearing mice. The metabolite also alters the depleted 
hematological parameters like red blood cell, white blood cell, hemoglobin (Hb%), etc. towards 
normal in tumor bearing mice. Metabolite show no adverse effect on liver functions regarding 
blood glucose, serum alkaline phosphatases, glutamic pyruvic transaminase, glutamic oxaloacetic 
transaminase activity and serum billirubin, etc. in normal mice. Histopathological observation 
of these mice organ does not show any toxic effect on cellular structure. But in the case of EAC 
bearing untreated mice these hematological and biochemical parameters deteriorate extremely 
with time whereas petroleum ether extract bacterial metabolite receiving EAC bearing mice 
nullified the toxicity induced by EAC cells. 
Conclusion: Study results reveal that metabolite possesses significant antiproliferative and 
hepatoprotective effect against EAC cells.
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of action of some strains is through the production of cytotoxic 
factors, enzymes, antibiotics and others secondary metabolites 
that can be used or adapted in a proper manner to specifically 
target cancer cells. Interestingly, bacteria naturally produce 
several chemokine/adhesion receptor inhibitors, so this 
appears as a new appealing approach as an anticancer 
therapy such as superantigen produced by Staphylococcus 
aureus showed anticancer activity against different types of 
cancer by interacting with cell surface receptors[2,3]. Bacterial 
enzymes arginine deaminase of Mycoplasma arginini act as 
candidate therapeutic agents for cancer treatment and show 
potential antitumor activity against different cancer in vivo 
and in vitro as well as inhibit the growth of HIV and hepatitis C 
virus by depletion of arginine[4,5]. Exotoxin A-immunotoxins 
kill cancer cells by binding specifically to overexpress 
cell-surface receptors, where they arrest protein synthesis 
and induce apoptosis and showed positive result against 
leukemia and bladder cancer in clinical trial[6-8]. Microbial 
secondary metabolites, such as manumycin A (fernesyl 
trasferase) and gliotoxin showed both in vitro cytotoxic 
activities against several cell lines and in vivo against human 
cancer xenografted models[9,10]. Prodiginines are bacterial 
secondary metabolites has been shown anticancer activity 
in several cancer derived cell lines and also in vivo in mice 
with a xenografted liver cancer by inducing apoptosis[11]. 
Epothilones were discovered as cytotoxic metabolites in the 
myxobacterium Sorangium cellulosum. They show anti-
tumor activity in cancer cell lines inducing its polymerization 
and stabilization which causes cell cycle arrest at the G2/M 
transition and apoptosis[12]. 
   Microbial-based therapy of cancer is one of the emerging 
cancer treatment modalities. Over the past few years, 
important advances have been made to study and develop 
bacterial products with cancer killing ability. Attention has 
also recently been directed to the use of bacterial products 
that can enter preferentially to cancer cells and disrupt their 
growth or kill them by multiple mechanisms. We report 
experimental tumor mouse model as it have great importance 
in developing potential drugs using Ehrlich ascites 
carcinoma (EAC) because EAC cell is one of the commonest 
tumors which is referred to as an undifferentiated carcinoma 
and is originally hyperdiploid, has high transplantable 
capability, no-regression, rapid proliferation, shorter life 
span, 100% malignancy and resembles to human tumors 
which are the most sensitive to chemotherapy[13]. Anticancer 
activity of secondary metabolites extracted from cultured 
bacteria against EAC cells was investigated to find out 
effective host friendly anticancer drugs.
2. Materials and methods
2.1. Chemicals and reagents
   All the chemicals and reagents used throughout the 
investigation were of reagent grade and from BDH, England, 
E’MERK, Germany and Sigma Aldrich, USA.   
2.2. Test animals
   Adult male Swiss albino mice, six to eight weeks old [(25依
5) g body weight] were collected from animal resource branch 
of the International Centre for Diarrheal Disease Research, 
Bangladesh (ICDDR’B) and used throughout the studies. 
Animals were housed in polypropylene cages containing 
sterile paddy husk as bedding material under hygienic 
conditions with a maximum of ten animals in a cage. They 
were maintained under controlled conditions (12:12 h light-
dark), temperature (22依5) °C. The mice were fed with standard 
mice food-pellets (collected from ICDDR’B) and water was 
given in ad libitum. 
2.3. Cell lines
   EAC cells were obtained by the courtesy of Indian Institute 
of Chemical Biology (IICB), Kolkata, India. The cells were 
maintained as ascites tumour in swiss albino mice by 
intraperitoneal inoculation (biweekly) of 2伊106 cells/mouse.
2.4. Ethical clearance
   Protocol used in this study for the use of mice as animal 
model for cancer research was approved by the Institutional 
Animal, Medical Ethics, Biosafety and Biosecurity Committee 
(IAMEBBC) for Experimentations on Animal, Human, Microbes 
and Living Natural Sources (225/320-IAMEBBC/IBSc), Institute 
of Biological Sciences, University of Rajshahi, Bangladesh.
2.5. Identification of bacteria and extraction of metabolites
   The isolated cellulytic soil bacteria were identified by their 
colony morphology, staining characters, pigment production, 
motility and other relevant biochemical test as per standard 
methods[14,15]. The isolated pure bacteria were cultured in 
broth media at 37 °C for 72 h and then centrifuge the media 
at 8 000 r/min for 10 min. The supernatant was collected and 
the secondary metabolites produced by the bacteria were 
extracted with petroleum ether. The solvent was evaporated 
by rotary evaporator and the semisolid metabolites designated 
as petroleum ether bacterial metabolites (PEBM), preserved in 
decicator for further use.
2.6. Determination of median lethal dose (LD50)
   The bacterial metabolites (PEBM) was dissolved in distilled 
water and were injected intraperitoneally to eight groups 
of mice (n=4) at different doses of [100 mg/kg (i.p.), 400 mg/
kg (i.p.), 800 mg/kg (i.p.), 1 200 mg/kg (i.p.), 1 600 mg/kg (i.p.), 
1 800 mg/kg (i.p.), 2 000 mg/kg (i.p.) 2 100 mg/kg (i.p.)]. The LD50 
value was then estimated by the procedure as described in 
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the literature[16].
2.7. Brine shrimp lethality bioassay
   Cytotoxicity of the metabolites was screened against 
Artemia salina in a 1-day in vivo assay according to 
published protocol[17]. For the experiment 3 mg of the 
metabolite was dissolved in 0.6 mL (600 µL) of distilled water 
to get a concentration of 5 µg/µL and by serial dilution 
technique, solutions of varying concentrations such as 5, 
10, 20, 40, 80 and 100.0 µg/mL were obtained. After 24 h. 
of incubation, the percentage of mortality of the nauplii 
was calculated for each concentration and the LC50 value 
was determined using Probit analysis as described in the 
literature.
2.8. Determination of cell growth inhibition (in vivo)
   To determine the cell growth inhibition[18] of the 
metabolites, five groups of Swiss albino mice (n=6) were 
used. For therapeutic evaluation 136伊104 EAC cells in every 
mouse were inoculated on day 0. Treatments were started 
after 24 h of tumor inoculation and continued for 5 d. Group 
one to three received the metabolite at the doses of 25 mg/
kg (i.p.), 50 mg/kg (i.p.), and 100 mg/kg (i.p.). Group four 
received bleomycin at the dose of 0.3 mg/kg/day[19] (i.p.) and 
group five was used as control. Mice in each group were 
sacrificed on day six and the total intraperitoneal tumor 
cells were harvested by normal saline (0.98%). Viable cells 
were first identified by using trypen blue and then counted 
by a haemocytometer. Total number of viable cells in every 
animal of the treated groups was compared with those of 
control (EAC treated only) group. 
2.9. Bioassay of EAC cells
   In this experiment[20] three groups of mice (n=6) were 
inoculated with 115伊105 EAC cells. Group 1 and 2 was treated 
with the bacterial metabolites and bleomycin at the dose 
of 100 and 0.3 mg/kg (i.p.) respectively for five consecutive 
days and group 3 served as control. On day 7, tumor cells 
from the mice were harvested in cold (0.9%) saline, pooled, 
centrifuged and re-inoculated (2伊105 cells/mice) into 3 fresh 
groups of mice (n=6) as before. No further treatment was 
done on these mice. On day 5, they were sacrificed and 
viable tumor cells count/mice were performed.
2.10. Determination of average tumor weight and survival time
   For this determination, a brief description of the method[21] 
used is given bellow; five groups of Swiss albino mice (6 
in each group) were used. For therapeutic evaluation 136伊
10
4 EAC cells per mouse were inoculated in to each group 
of mice on day 0. Treatment was started after 24 h of tumor 
cell inoculation and continued for 10 d. Tumor growth 
were monitored by recording daily weight change and host 
survival was recorded and expressed as mean survival time 
in days and percent increase of life span was calculated by 
using the following formula:                                   
Mean survival time (MST) =    
∑Survival time (days) of each mouse in a group
Total number of mice
Percent increase of life span (ILS) % ={ }MST of treated groupMST of control group 伊 100-1
2.11. Monitoring of the hematological profile
   To assess the effects of PEBM on the hematological 
parameters like WBC, RBC, Hb content, etc. were determined 
by the standard methods[22] using cell dilution fluids 
and hemocytometer. For this purpose, four groups (n=24) 
of mice were taken. Group 1, normal mice (without any 
treatment), group 2 EAC bearing control mice (only EAC 
treated), group 3 and group 4, normal mice treated with 
PEBM and EAC bearing mice treated with PEBM at 100 mg/
kg/d (i.p.) respectively. Blood was collected from six mice 
of each group on day 5, 10, 15 and 25 by tail puncture in 
anticoagulant containing tube.
2.12. Measurement of biochemical parameters
   The parameters such as serum GPT (glutamic pyruvic 
transaminase), GOT (glutamic oxaloacetic transaminase), ALP 
(alkaline phosphatases), serum glucose, cholesterol, urea, 
billirubin, triglyceride, etc. were determined for both normal 
and EAC bearing mice. For this experiment, on day 5, 10, 15 
and 25, six mice from each group were sacrificed. Blood was 
collected from heart in plastic centrifuge tubes. These were 
then allowed to clot at room temperature for half an hour 
and centrifuged at 4 000 r/min for 15 min using a WIFUNG 
centrifuge LABOR-50M. The clear straw colored serum was 
then collected from the upper part of the tubes in vials 
with a micro-pipette. All the parameters were determined 
according to the procedures[23] established earlier.
2.13. Effect of metabolites on normal peritoneal cells
   Effects of PEBM on normal peritoneal cells were 
determined[20] by counting total peritoneal cells and number 
of macrophages. Normal mice (6 in each group) were treated 
with PEBM (i.p.) at the dose of 25 mg/kg, 50 mg/kg and 100 
mg/kg for three consecutive days. The untreated group was 
used as control. After 24 h of last treatment animals were 
sacrificed after injecting 5 mL of normal saline (0.98%) into 
peritoneal cavity of each mouse. Intraperitoneal exuded cells 
and number of macrophages were counted with 1% neutral 
red by haemacytometer.
2.14. Histopathology
   The major body organs like brain, liver, kidney, heart, lung 
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and spleen, were collected from the experimental animals 
on 15th day and processed by standard methods[23] to 
prepare slides of tissues by hematoxylin and eosin staining. 
The slides were viewed under Motic Advanced system 
microscope (B, series) with the help of Motic J. 1 software in 
a Macintosh computer. PEBM induced hepatotoxicity as well 
as toxicity on other organs was observed.
2.15. Statistical analysis
   The experimental results have been expressed as the mean
依SEM (Standard Error of Mean). Data have been calculated by 
one way ANOVA followed by Dunnett ‘t’ test using statistical 
package for social science (SPSS) software of 10 version.
3. Results
3.1. Median lethal dose (LD50)
   The LD50 value of the metabolites from Corynebacterium 
xerosis was found to be 1 050 mg/kg (i.p.) for intraperitoneal 
treatment in male Swiss albino mice. The experimental 
animal showed toxicity at this dose regarding body weight or 
general appearance. 
3.2. Brine shrimp lethality bioassay
   The brine shrimp lethality bioassay was done to assess the 
in vitro cytotoxic effect of the metabolites. Medium lethal 
concentration (LC50) of brine shrimp lethality was found to 
be 22.49 µg/mL and percent of mortality of nauplii were 
increases with the concentration of PEBM (Figure 1).
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Figure 1. Effects of PEBM on the mortality of brine shrimp nauplii.
3.3. Cell growth inhibition (in vivo)
   Maximum cell growth inhibition was found with the 
treatment of metabolites at the doses 100 mg/kg (i.p.) and 50 
mg/kg (i.p.), as evident from 78.56% and 66.5% reduction of 
tumor cells respectively whereas treatment with bleomycin at 
dose 0.3 mg/kg showed 89.57% cell growth inhibition (Figure 2)
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Figure 2. Effects of PEBM on EAC cell growth inhibition.
Results are shown as mean依SEM, where significant values are *P<0.05, 
**P<0.01 and ***P<0.001 when compared with control (EAC bearing only).
*
** ***
3.4. Bioassay of EAC cells
   Transplantability of EAC cell treated with PEBM was found 
to be decreased remarkably as 72.4% reduction in EAC cell 
growth was observed when 5 d treated (at the dose 100 mg/
kg i.p.) EAC cells were re-inoculated into fresh mice and 
sacrificed on day 5.
3.5. Tumor weight and survival time
   An effective chemo-preventive anti-cancerous drug shows 
a significant increase on survival time of EAC cell bearing 
mice. The effect of metabolites on survival time at different 
doses was summarized in Figure 3. It has been observed that 
tumor bearing mice treated with the PEBM at doses 25 mg/kg 
(i.p.), 50 mg/kg (i.p.), and 100 mg/kg (i.p.) resulted in, increase 
of life span significantly, when compared to that of control 
mice. Thus the survival time was found to be increased 
when the dose of the metabolites was increased. Bleomycin 
increased life span by 82.00% when compared to control. It 
was observed that % of increase of life span of mice at dose 
of 100 mg/kg (i.p.) of the test metabolite is quite comparable 
(69.23% P<0.01) to that of standard anticancer agent bleomycin 
(0.3 mg/kg).
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Figure 3. Effects of PEBM on survival time of tumor bearing mice        
Results are shown as mean依SEM, where significant values are *P<0.05, 
**P<0.01 and ***P<0.001 when compared with control (EAC bearing only).
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***
**
   Effect of bacterial metabolites at the doses of 25 mg/kg, 50 
mg/kg, 100 mg/kg and the antitumor drug bleomycin (0.3 mg/
kg) on average tumor weight is shown in Figure 4. Treatment 
of the animals with PEBM, previously inoculated with EAC 
cells, resulted in the inhibition of tumor growth. In the case 
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of control (EAC bearing) group, the body weight was increased 
by 81.22% in 20 d when compared to the normal. Mice treated 
with bacterial extract at the doses of 25 mg/kg (i.p.), 50 mg/kg 
(i.p.) and 100 mg/kg (i.p.) the body weight increased only by 
47.34%, 36.85%, 28.44%, respectively on 20 d. 
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Figure 4. Effects of PEBM on tumor weight of EAC bearing mice.
Results are shown as mean依SEM, where significant values are *P<0.05, 
**P<0.01 and ***P<0.001 when compared with control (EAC bearing only).
*
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3.6. Effect of PEBM on hematological parameters
   The hematological parameters like RBC, WBC, Hb, etc of both 
treated and non-treated mice were examined. For normal 
mice receiving PEBM at 100 mg/kg/day, all the examined 
parameters were found to be slightly changed during the 
treatment period from normal values. After 25 d of the initial 
treatment they were restored to almost normal values. In 
the case of parallel treatment of EAC bearing mice, these 
parameters were found to be significantly deteriorated as 
compared to those of the normal mice due to tumorogenesis. 
But these deteriorated parameters reverse towards normal 
values when treated with PEBM at dose 100 mg/kg (i.p.). All the 
experimental data are presented in Table 1.
Table 1
Effects of PEBM on hematological parameters in normal and 
experimental mice.
Name of Exp. Days RBC Cells/mL WBC Cells/mL % of Hb (g/dL)
Normal mice  0 (6.80依0.67)伊109  (9.45依1.61)伊106 11.00依1.20
Normal+PEBM  5  (4.69依0.27)伊10
9a   (6.97依0.85)伊106c    5.80依0.32c
10  (5.14依0.75)伊109b   (7.12依1.00)伊106b    6.88依0.91c
15 (5.71依0.22)伊109 (10.30依2.70)伊106   5.50依2.10
25 (5.85依0.41)伊109   (9.75依1.20)伊106b 12.00依1.10
EAC control  5 (4.20依0.31)伊10
9
(13.00依0.34)伊106   9.10依0.11
10 (3.80依1.40)伊109 (15.00依1.30)伊106   7.70依0.36
15 (3.20依0.14)伊109 (17.00依0.31)伊106   5.60依0.40
25  (2.32依0.20)伊109*  (25.70依0.40)伊106*     4.00依1.00**
EAC+ PEBM  5 (3.80依1.10)伊10
9
(15.80依3.10)伊106   6.70依2.10
10 (4.10依1.40)伊109 (14.00依1.30)伊106  7.20依1.30
15 (4.30依1.20)伊109 (11.00依3.40)伊106  7.40依1.10
25 (5.70依1.20)伊109 (10.90依2.70)伊106  8.10依2.30
Results are shown as mean依SEM, where significant values are aP<0.05, 
bP<0.01 and cP<0.001 when PEBM treated mice compared with normal mice 
and *P< 0.05 and **P<0.01 when (EAC+PEBM) treated mice compared with EAC 
bearing controlmice (EAC bearing only).
3.7. Effect of PEBM on enzymes
   Effects of the metabolites on the enzyme activities like 
GPT, GOT and ALP have been presented in Figure 5-7. With 
normal mice, activities of these enzymes were found to 
be moderately increased during the treatment period (14 
consecutive days at dose 100 mg/kg/day i.p.), after which 
these values were gradually return to the more or less 
normal level. For EAC bearing untreated mice, all such 
values increased almost linearly with time while EAC bearing 
mice treated with PEBM however, limit the increment of GPT, 
GOT and ALP values remarkably. After treatment, the GPT 
values returned to normal levels with time (Figure 5-7) while 
the ALP values reduced effectively (Figure 5 and 6). In the 
case of GOT, the test metabolite partially reduced the rate of 
its increment (Figure 7).
Figure 5. Effects of PEBM on SGPT of experimental mice.
Results are shown as mean依SEM.
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Figure 6. Effects of PEBM on SALP of experimental mice.
Results are shown as mean依SEM.
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Figure 7. Effects of PEBM on SGOT of experimental mice.
Results are shown as mean依SEM.
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3.8. Effect of PEBM on biochemical parameters
   Table 2 shows the effects of PEBM on serum biomolecules 
such as glucose, bilirubin, cholesterol, urea, triglyceride 
and creatinine content of both normal and EAC bearing mice. 
All these parameters except glucose were increase in both 
normal and EAC bearing mice but they regain to its normal 
range in PEBM treated normal mice after the treatment. 
This values return back to more or less normal level in EAC 
bearing mice treated with PEBM. The glucose content was 
found to be increased to some extent during the treatment 
period in normal mice, after the treatment period, it slowly 
reversed back towards normal level. For EAC bearing mice, 
the glucose content was found to be reduced abruptly from 
normal level due to hypoglycemic effects of EAC cells. The 
supplementation of PEBM increased the glucose value close 
to normal level.
3.9. Effect of PEBM on peritoneal cells
   The average number of peritoneal exudates cells of normal 
mice treated with the metabolite were found to be (20.0依
1.7)伊106 of which the macrophage counts were (5.06依0.15)伊
10
6. Treatment with PEBM at dose 100 mg/kg/day for three 
consecutive days significantly enhanced the number of 
macrophages. Results are shown in Figure 8.     
Figure 8. Effects of PEBM on enhancement of peritoneal cells.
Results are shown as mean依SEM, where significant values are **P<0.01 and 
*** P<0.001 when compared with control (normal mice).
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3.10. Histopathology
   Histology of major organs like liver, kidney, heart, lung, 
spleen and brain were performed to observe any changes 
in tissues level (infiltration, inflammation, congestion, 
degradation and regeneration, etc) of the mice receiving 
the metabolite at dose 100.0 mg/kg/day for 14 consecutive 
days with respect to control group (normal mice). In mice 
of the treated group (normal mice receiving PEBM), no 
abnormalities in the histopathology of kidney, spleen, 
lung and brain were detected in comparisons with control 
(receiving saline only) group under microscope. Liver 
tissues showed very little infiltration with no central vein 
dilation, fatty generation or nodule formation, necrosis etc 
in normal mice whereas major organs of EAC bearing mice 
showed significant cellular degeneration/regeneration 
due to carcinogenesis. The hepatotoxicity induced by 
EAC cells were nullified by the protective effects of PEBM 
supplementation to a great extent (Figure 9).
Table 2
Effect of PEBM on biochemical parameters in experimental mice.
Name of Exp. Days
Serum glucose
 mg/dL blood
Serum cholesterol 
mg/dL blood
Serum billirubin 
mg/dL blood
Serum urea 
mg/dL blood
Serum triglyceride 
mg/dL blood
Serum creatinine 
mg/dL
Normal mice  0 152.3依1.3 142.7依3.5 1.32依0.10 37.2依4.2 110.0依2.5 0.26依0.21
Normal 
+PEBM
 5    102.0依10.5b 155.5依7.3 1.07依0.20 26.0依2.7 140.5依5.0 0.29依0.20
10 138.7依8.3   221.0依15.7 1.59依0.10 38.5依5.1 162.0依6.0 0.35依0.10
15   170.0依12.6a  235.0依5.0a  1.77依0.30c 48.8依7.5  172.8依5.3c 0.45依0.15
25  156.0依14.0 160.7依6.4 1.45依0.25 39.6依4.4 120.0依5.7 0.28依0.10
EAC control  5   87.0依2.3
*
152.0依3.7 1.52依0.50  64.1依1.8* 188.6依6.2 0.40依0.20
10    73.0依3.7** 156.7依2.6 1.95依0.63  77.0依0.8* 192.0依3.1 1.10依0.31
15    65.0依2.4** 165.0依3.7 2.40依0.45   84.1依1.2**    205.0依5.2** 2.70依1.10
25    54.3依2.9**   183.0依3.8** 2.45依1.10    93.0依3.1***     231.0依3.1***   3.20依1.20**
EAC+ PEBM  5  96.5依4.5 142.0依3.3 1.50依0.25 47.3依4.3  158.0依2.2
*
0.81依0.40
10   92.2依10.4 155.0依4.6 1.75依0.40 50.5依2.5 172.1依8.2 0.92依0.20
15  90.5依6.5 165.4依2.5 1.85依0.43 55.2依2.5 178.0依1.2 1.00依0.50
25  88.5依8.5 175.0依5.1 1.92依0.54 62.2依5.3 198.2依1.5 1.30依1.00
Results are shown as mean依SEM, where significant values are aP<0.05, bP<0.01 and cP<0.001 when PEBM treated mice compared with normal mice and 
*P<0.05 
and **P<0.01 when (EAC+PEBM) treated mice compared with EAC bearing controlmice (EAC bearing only).
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Figure 9. Histopathological examinations of experimental mice.
A: Liver tissues from control mice with no abnormality; B: Liver tissue from PEBM 
treated normal mice shown very little infiltration with no central vein dilation, 
fatty generation or nodule formation; C: Liver tissues from untreated EAC bearing 
mice with necrosis, central vein dilation; D: Liver tissues from EAC bearing PEBM 
treated mice with very little necrosis and no central vein dilation.
A B
C D
4. Discussion
   The potency and efficacy of the metabolites as potential 
anticancer agent has been judged by measuring reduction 
of average tumor weight, cell growth inhibition and 
enhancement of life span of the EAC cell bearing mice 
as well as hematological parameters. The efficiency of 
the metabolites has been compared with data obtained 
by running parallel experiments with a known effective 
clinically used anticancer drug, bleomycin at the dose of 0.3 
mg/kg (i.p.). The average tumor weight reduction ability of 
the metabolite has been examined. For tumor bearing mice, 
body weight has been found to be increased gradually with 
time. The treatment of such mice with PEBM has reduced 
the growth rate significantly. The metabolites also inhibits 
the cell growth rate effectively, more than 78.56% (P<0.001) 
inhibition has been achieved at dose 100 mg/kg (i.p.) which is 
quite comparable to that of bleomycin(0.3 mg/kg).
   The metabolites also increased the life span of tumor 
bearing mice very effectively. The potency has been found 
to be increased with the further enhancement of dose. In 
the present study, the dose up to 100 mg/kg (i.p.) has been 
employed only. Further enhancement of the life span of tumor 
bearing mice is therefore expected with still higher doses. 
The enhancement of life span has been assigned as a very 
important parameter for judging its suitability of a compound 
as potential chemopreventive anticancer agent[24].
   High LD50 value (1 050 mg/kg) indicates that PEBM has 
minor or no toxicity to the host which is also rectified by the 
hematological and histopathology studies as well.
   Hematological parameters for normal mice, EAC cell bearing 
mice and EAC bearing mice treated with the metabolites have 
been studied. Although the treatment of the metabolites in 
normal mice showed little toxic effect (during the treatment 
period), but they were found to be recovered back towards 
normal level after the treatment period. The effect is more 
pronounced in the case of EAC bearing mice. Literature reveals 
that progression of tumor was accompanied by the following 
hematological changes compared to normal gradual decrease 
in hemoglobin content, RBC count and gradual increase in 
leukocytes[19] which was also observed in our control mice. 
The RBC count was almost reversed back to normal range 
on the treatment of PEBM in EAC bearing mice. It could also 
improve the WBC level efficiently. The hemoglobin level was in 
the near normal range in the PEBM treated EAC bearing group. 
Recovery of the hematological parameters like hemoglobin 
content, RBC and WBC cells count in the experimental mice 
indicates the protective action of PEBM on the hemopoietic 
system and this certainly ratify that PEBM posses pronounced 
anticancer activity with a little or no host toxic effect.
   It has been found that the metabolites have significantly 
increased the peritoneal cells in normal mice. Treatment with 
the metabolites at dose 100 mg/kg (i.p.) increases the number 
of macrophages to great extent. This is considered to be a 
very important indicator for acquiring self destroying ability 
of the animals/ living beings towards cancer cells[20] by cell 
mediated immunity.  Enhancement of macrophages might 
produce some candidate cytokines such as tumor necrosis 
factors, interleukins, etc. inside the peritoneal cavity, which 
in turn may be responsible for killing of tumor cells[16]. The 
bioassay of EAC cells shows a significant reduction of viability 
of cancer cells in vivo after the treatment with PEBM.
   Hepatoprotective effects of PEBM have been performed by 
studying biochemical parameters as well as histopathological 
analysis of experimental animal. It is well known that there 
are significant elevations in the levels of serum GPT, GOT and 
ALP in liver diseases and disorders in hepatocellular damage 
caused by a number of agents. An increase in these enzyme 
levels is also observed in patients with cardiac damage due 
to myocardial infarction and with liver disorders[19].
   Biochemical measurements of these parameters in normal 
mice treated with PEBM showed some extent of increase 
due to mild hepatotoxicity during treatment period but they 
become normal after completion of treatment schedule. The 
slight host toxic effects observed in mice during treatment 
time are mostly reversible. This means that, the treatments of 
the extract do not cause any acute or permanent damage to 
the liver. But in case of tumor bearing mice, these parameters 
were found to be increase more drastically with time due to 
the acute and permanent toxicities induced by EAC cells on 
host. After treatment with PEBM in the EAC bearing mice these 
values remain near the normal range in the treated group. 
From this it follows that the damage generated by EAC was 
prevented by PEBM supplementation.
   Treatment of normal mice with PEBM slightly changed 
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biomolecules level which also rectified more or less to normal 
after treatment. This indicates that after short term treatment 
the extract did not cause any extreme abnormality at the dose 
used in this study.
   The development of hypoglycaemia and hyperlipidaemia 
in experimental animals with carcinoma has been previously 
reported[21]. In this experiment, the reduced glucose level 
and elevated cholesterol, triglycerides and serum urea were 
returned to more or less normal levels in PEBM-treated mice, 
thereby indicating a potent antitumour efficacy of PEBM.
   The histopathology of major organs of normal mice also 
revealed the relatively less toxic nature of the metabolite as 
compared to control group when viewed under microscope. 
The histopathology of kidney tissues from PEBM treated 
mice did not show any cellular regeneration/regenerations, 
glomerular infiltration, and there is no sign of tubular 
necrosis, casts and also glomerular congestion. Tissues 
from brain as well as other organs did not show changes 
in cellular architecture. The histology of liver showed very 
little infiltration (inflammation) with no central vein dilation, 
fatty generation or nodule formation in normal mice having 
PEBM. This mild hepatotoxicity causes some biochemical 
parameters deteriorate during treatment period which 
become normal after closing treatment. All these slight host 
toxic effects observed in mice during treatment time are 
mostly reversible and so treatment with PEBM do not cause 
any acute or permanent damage to the host. 
   Histology of EAC bearing mice showed major abnormities 
in almost all studied organs and it is interesting that the 
hepatic damage induced by EAC cells were nullified by PEBM 
supplementation.   
   The aim of this study was to determine the antiproliferative 
and hepatoprotective effects of the metabolite obtained from 
our isolated bacteria to find out less host toxic potential 
anticancer agents. The results presented above showed that 
the metabolites at dose 100.0 mg/kg (i.p.) can inhibit cell 
growth of tumor bearing mice satisfactorily, reduce tumor 
growth rate markedly and increase life span dramatically. 
All these parameters are considered as very important and 
promising aspects in justifying the potency of a compound 
in cancer chemopreventive therapy[24]. As the metabolites 
enhances macrophages and other peritoneal cells remarkably, 
so it is speculated that the metabolite kill or destroy tumor 
cells by boosting cell mediated tumor immunity of the host. 
One of the major problems usually encountered in cancer 
chemotherapy is myelosuppression followed by anemia[25]
due to the reduction of RBC and hemoglobin contents in host. 
This is probably owing to the deficiency of iron in hemolytic 
or myelopathic condition. The treatment with PEBM under 
investigation can also reverse all the depleted hematological 
parameters back towards almost normal level which indicate 
that it have protective effect on hemopoetic system. The 
host toxic effect of PEBM is not high and almost in all cases 
the toxic effects of EAC cells on biomolecules as well as on 
cellular structure have been found to be nullified by such 
treatment. In most cases antagonistic effects have been found 
instead of additive or synergistic effects. Further elevation 
of glucose levels of EAC bearing mice by the treatment of the 
metabolite indicates their partial recovery from tumor growth. 
   As the major organs of the treated mice do not show any 
histopathological abnormalities, these findings in conjunction 
with those obtained from the measurement of hematology 
and serum biomolecules definitely give positive support to 
conclude that PEBM is an effective antineoplastic agent with 
comparatively less toxic effects in our experimental model. 
However, further chronic toxicological studies and its anti-
tumor activity and its mechanism should be carried out 
against other tumor cell lines which may bring promising 
results in cancer chemotherapy. 
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Comments 
Background
   Toxicity of chemotherapy to host is main problem for its 
efficacy and outcome. Untoward side effects of available 
chemopreventive agents limit their application and usage. 
Therefore, host friendly and effective chemo-agents 
discovery and development is needed for cancer treatment 
with better outcome.
  
Research frontiers
   The present research work explores the anticancer and 
hepatoprotective activities of secondary metabolites extracted 
from a bacterial species namely Corynebacterium xerosis 
against EAC cells in animal model. Its anticancer activity 
was determined by observing different parameters like 
tumor weight, survival time, cell growth inhibition and the 
hepatoprotective effects of the metabolites was measured by 
studying biochemical and histological studies.
Related reports
   Many microbial metabolites/products show important 
pharmacological properties and used as antibiotic, anticancer 
agents, enzyme inhibitors etc. Bacterial products like 
exotoxin A, manumycin, gliotoxin showed in vitro cytotoxic 
activity against different cell lines. Some metabolites induce 
apoptosis of different cancer cell both in vitro and in vivo.
Innovations and breakthroughs
   To find out an effective, cheap and host friendly anticancer 
agents from nature, anticancer and hepatoprotective 
activity of the metabolites carried out. The authors first time 
reported the hepatoprotective and antiproliferative potential 
of metabolites extracted from the Corynebacterium xerosis 
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against EAC cell in vivo.
  
Applications
   The data obtained from the study is very much promising 
and lead to further studies in this field. This study may open 
new biotechnological approaches to find effective cancer 
chemo-agents from microbes.    
Peer review
   This is an excellent and well designed research work 
in which the researchers have explore the anticancer and 
hepatoprotective activity of metabolites from Corynebacterium 
xerosis against EAC cells in Swiss albino mice. Cell growth 
inhibition, survival time, tumor weight and hematological 
parameters were studied to assess its anticancer activity. 
Biochemical and histopathology of mice organ were studied 
for its hepatoprotective potential. It was found from the 
study that the metabolites have promising anticancer and 
hepatoprotective activity in mice model.
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